Lipoproteína(a)
Grupo Argentino Estudio Lipoproteína (a)
.png)
Novedades Abril 2026
PLoS One. 2026 Feb 23;21(2):e0342704. doi: 10.1371/journal.pone.0342704. eCollection 2026.
Autores:
Mengru Wang 1 , Fudong Hu 2 , Rongyan Jiang 1 , Sheng Tu 1
Conclusión: The Lp(a)-CatLet© synergy enhances MACCE risk stratification in ePCI-treated AMI, reflecting complementary pathobiological (Lp(a)-driven plaque vulnerability) and anatomical (CatLet©-quantified complexity) pathways. This dual-parameter approach could support post-PCI risk stratification and follow-up planning.
Cardiol J. 2026:33:e00226010. doi: 10.5603/cj.108082. Epub 2025 Oct 16.
Autores:
Tomasz Saniewski 1 2 , Grzegorz Procyk 3 4 , Jakub Zimodro 3 4 , Olivia Wasilewska 5 , Bartosz Mroczyk 5 , Michał Lis 5 6 , Aleksandra Gąsecka 3
Conclusión: High Lp(a) is prevalent in the Polish population, and thus it is important to measure it routinely in each individual at least once in a lifetime and control all other known cardiovascular risk factors to decrease the overall risk.
Curr Opin Lipidol. 2026 Apr 1;37(2):65-72. doi: 10.1097/MOL.0000000000001030. Epub 2026 Feb 6.
Autores:
Stefan Coassin 1
Conclusión: Technological advances establish a foundation for more accurate genetic risk assessment across ancestries. These advances are enhancing our understanding of Lp(a) regulation and build a framework for future integrative genetic studies, which may shed new light on the evolution of the Lp(a) trait, adding important context for its physiological and clinical relevance.
Curr Opin Lipidol. 2026 Apr 1;37(2):58-64. doi: 10.1097/MOL.0000000000001024. Epub 2026 Jan 28.
Autores:
Arya Aminorroaya 1 2 , Rohan Khera 1 2 3 4 5
Conclusión: Machine learning-based strategies provide a scalable means of operationalizing universal Lp(a) testing recommendations within health systems. When developed using unbiased data, externally validated, and assessed for fairness and interpretability, these models can support systematic identification of individuals with elevated Lp(a) and integration of Lp(a) measurement into routine cardiovascular risk assessment.
J Clin Lipidol. 2026 Feb;20(2):317-325. doi: 10.1016/j.jacl.2025.12.002. Epub 2025 Dec 4.
Autores:
Shoshana H Bardach 1 , Skye Chernichky-Karcher 2 , Allison Hawke 3 , Diane MacDougall 3 , Katherine Wilemon 3 , Laurence S Sperling 4
Conclusión: This analysis highlights that Lp(a) testing decisions are multifactorial, providing multiple opportunities for intervention and improvement. Strategies to convey how Lp(a) measurement can inform risk assessment and treatment approaches may be foundational to encouraging more widespread testing.
Am J Med Sci. 2026 Mar;371(3):274-280. doi: 10.1016/j.amjms.2025.09.009. Epub 2025 Dec 21.
Autores:
Brian Brereton 1 , Rupak Desai 2 , Pratiksha Shankarlal Nathani 3 , Shisheer Havangi Prakash 4 , Amritha Nair 5 , Chantal Lewis 6 , Amreen Sidhu 7 , Sadiya Usman 8 , Shaylika Chauhan 9 , Vinutha Akki Vivekanand 10 , Athmananda Nanjundappa 11 , Praveena Sunkara 12
Conclusión: There is some evidence that Lp (a) levels are an independent risk factor for MACE in patients who underwent PCI for CAD. There is also some evidence that elevated Lp (a) levels are associated with a worse prognosis in patients with DM after PCI, but this association is not consistent in the literature. Further prospective multicenter studies are required in order to elucidate this association.
Clin Investig Arterioscler. 2026 Mar-Apr;38(2):500870. doi: 10.1016/j.arteri.2025.500870. Epub 2025 Oct 18.
Autores:
Rosa Fernández-Olmo 1 , Jesús Lara Mariscal 2 , Ana García Ruano 3 , Alberto Cordero 4 , Juan Manuel Castillo Casas 5 , Diego Franco 5
Minerva Cardiol Angiol. 2026 Feb;74(1):128-134. doi: 10.23736/S2724-5683.24.06534-7. Epub 2024 Jun 5.
Autores:
Gianmarco Cancelli 1 , Lamia Harik 1 , Mudathir Ibrahim 2 , Irbaz Hameed 3 , Camilla Rossi 1 , Tulio Caldonazo 1 , Michele Dell'aquila 1 , Giovanni J Soletti 1 , Kevin R An 1 , Jordan Leith 1 , Michelle Demetres 4 , Arnaldo Dimagli 1 , Mario F Gaudino 5
Conclusión: Studies evaluating the impact of Lp(a) on outcomes in CABG patients are few, with heterogenous cut-offs and outcomes. In the limited published studies, Lp(a) level was not associated with graft occlusion.
J Assoc Physicians India. 2026 Feb;74(2):33-37. doi: 10.59556/japi.74.1331.
Autores:
Sonali Sharma 1 , Ramesh Kumar Chandak 2 , Krishna Kumar Sharma 3 , Soneil Guptha 4 , Rajeev Gupta 5
Conclusión: Substantial variation in coronary artery disease (CAD) risk prediction using various clinical algorithms is observed in T2D. The EAS algorithm provides the most robust estimate. The addition of Lp(a) to the risk algorithms augments risk stratification significantly. The results of this pilot study need confirmation with larger prospective studies.
Pharmacol Ther. 2026 May:281:109010. doi: 10.1016/j.pharmthera.2026.109010. Epub 2026 Feb 20.
Autores:
Elias Björnson 1 , Chris J Packard 2 , Jan Borén 3
Am J Med Sci. 2026 Apr;371(4):336-344. doi: 10.1016/j.amjms.2025.12.002. Epub 2025 Dec 5.
Autores:
Yan-Yan Li 1 , Hui Wang 2 , Yang-Yang Zhang 3
Conclusión: LPA rs3798220 and rs10455872 polymorphisms were significantly associated with increased CAD risk. The persons carrying C allele of LPA rs3798220 and G allele of LPA rs10455872 polymorphisms might have higher CHD risk than the T allele of rs3798220 or A allele of rs10455872 carriers.
Lipids. 2026 Mar;61(2):265-274. doi: 10.1002/lipd.70025. Epub 2025 Nov 30.
Autores:
Clara M Howell 1 , Liv Hald Nyhave 1 , Bent Raungaard 1 2 , Aase Handberg 1 3 , Claus Gyrup Nielsen 3 , Christian Bork 1 2 , Stine Krogh Venø 1 3
Lakartidningen. 2026 Mar 20:123:25150.
Autores:
Elias Björnson 1 , Jonas Brinck 2 , Emil Hagström 3 , Jan Borén 4
Circ Popul Health Outcomes. 2026 Mar;19(3):e013261. doi: 10.1161/CIRCOUTCOMES.125.013261. Epub 2026 Feb 20.
Autores:
Ashkan Abdollahi 1 2 , Aysa Ostovaneh 2 , Omar Chehab 2 , Malak Hoballah 2 , Bruna R S Matuck 2 , Colin O Wu 3 , Seamus P Whelton 4 , Bharath Ambale-Venkatesh 5 , Wendy S Post 2 , David A Bluemke 6 , Michael Y Tsai 7 , Sotirios Tsimikas 8 9 , João A C Lima 2 5
Conclusión: Elevated Lp(a) levels were independently associated with maladaptive left ventricular and left atrial remodeling in Hispanic adults over a decade, while no statistically significant relationships were observed in White, Black, and Chinese participants. This suggests a unique susceptibility of Hispanic individuals to Lp(a)-mediated cardiovascular remodeling, independent of ischemic pathways.
J Clin Lipidol. 2026 Mar;20(3):671-676. doi: 10.1016/j.jacl.2026.01.018. Epub 2026 Jan 27.
Autores:
Jadry Gruen 1 , Archna Bajaj 2
Conclusión: Ahead of results from ongoing clinical trials testing Lp(a)-targeted therapies, health systems can use QI methods to assess current Lp(a) ordering practices, identify patients who may benefit from future Lp(a)-targeted therapy, and plan for rapid expansion of Lp(a) testing.
J Clin Lipidol. 2026 Mar;20(3):600-608. doi: 10.1016/j.jacl.2026.01.015. Epub 2026 Jan 27.
Autores:
Matteo Paolucci 1 , Giacomo Urbinati 2 , Mauro Gentile 1 , Stefano Forlivesi 1 , Giorgia Arnone 1 , Ludovica Migliaccio 1 , Maria Maddalena Viola 1 , Simone Galluzzo 3 , Cristiano Fanciulli 2 , Mario Sebastiani 1 , Eric Ramazzotti 4 , Rita Mancini 4 , Luigi Simonetti 3 , Andrea Zini 5
Conclusión: Higher Lp(a) values are associated with LAA stroke, particularly ICAS. Lp(a) levels should be included in the stroke workup.
Curr Med Res Opin. 2026 Jan;42(1):19-24. doi: 10.1080/03007995.2026.2627735. Epub 2026 Feb 11.
Autores:
Andreas Tridimas 1 2 , Suha Ahmed 3
Conclusión: Routine Lp(a) testing meaningfully alters management and reveals a form of residual dyslipidaemia resistant to standard therapy. These findings, combined with recent cost-effectiveness modelling showing NHS and societal savings from one-time testing, support incorporation of Lp(a) measurement into universal cardiovascular risk assessment.
J Clin Lipidol. 2026 Mar;20(3):609-619. doi: 10.1016/j.jacl.2025.12.016. Epub 2025 Dec 23.
Autores:
Dimitrios Delialis 1 , Polyxeni Manifava 1 , Sofia-Panagiota Giannakopoulou 2 , Christina Konstantaki 1 , Stavros Athanasopoulos 1 , Georgios Zervas 1 , Panagiotis Nastatos 1 , Georgios Mavraganis 1 , Kateryna Sopova 3 , Maria-Angeliki Dimopoulou 1 , Lydia Kokkinidou 1 , Yannis Skoumas 4 , Christos Pitsavos 4 , Nikolaos Rachiotis 1 , Lasthenis Angelidakis 1 , Dimitrios Papoutsis 1 , Peggy Kostakou 1 , Elisabeth Samouilidou 5 , Achilleas A Zacharoulis 6 , Konstantinos Stellos 7 , Evangellos Liberopoulos 8 , Christina Chrysochoou 4 , Georgios Georgiopoulos 1 , Demosthenes Panagiotakos 2 , Kimon Stamatelopoulos 9
Conclusión: Elevated Lp(a) levels were observed in 8.3% of the general population cohort and up to 23.9% in participants with ASCVD from the lipid clinic cohort, highlighting a risk gradient across ASCVD categories. Incorporating Lp(a) as a risk enhancer improves ASCVD risk reclassification beyond the validated HellenicSCOREII+.
Diabetes Obes Metab. 2026 Apr;28(4):3044-3053. doi: 10.1111/dom.70491. Epub 2026 Jan 21.
Autores:
Zenglei Zhang 1 , Lin Zhao 2 , Zeyu Wang 1 , Xianliang Zhou 1 , Xianlun Li 2 , Weixian Yang 1 , Xu Meng 1
Conclusión: Elevated Lp(a) levels were associated with a higher risk of ASCVD across different glucose metabolism statuses, particularly among individuals with NGR and prediabetes, independent of baseline CRP levels.
Endocr Regul. 2026 Mar 24;60(1):1-11. doi: 10.2478/enr-2026-0001. Print 2026 Jan 1.
Autores:
Heri-Nugroho 1 , Nurdopo Baskoro 2 , Charles Limantoro 3 , Andreas Arie Setiawan 3 , Anugrah Riansari 1 , Risa Ardiani 4
Glob Heart. 2026 Mar 23;21(1):25. doi: 10.5334/gh.1540. eCollection 2026.
Autores:
Szilard Voros 1 , Michael R Barnes 1 , David Watson 2 , Wess Boatwright 3 , Anthony Lozama 3 , Denise Yates 4 , Jagat Narula 5 , Santica Marcovina 6
J Lipid Res. 2026 Mar;67(3):101008. doi: 10.1016/j.jlr.2026.101008. Epub 2026 Feb 23.
Autores:
Santica M Marcovina 1 , Spenser Smith 2 , Lizhu Lin 3 , Sotirios Tsimikas 4
Clin Chem Lab Med. 2026 Feb 16;64(5):1064-1073. doi: 10.1515/cclm-2026-0149. Print 2026 Apr 24.
Autores:
1 Department of Clinical Chemistry and Laboratory Medicine, Leiden Apolipoprotein Reference Laboratory, 4501 Leiden University Medical Center , Leiden, The Netherlands.
J Lipid Res. 2026 Mar;67(3):100996. doi: 10.1016/j.jlr.2026.100996. Epub 2026 Feb 10.
Autores:
Lizhu Lin 1 , Fei Su 1 , Calvin Yeang 1 , Sotirios Tsimikas 2
J Cardiovasc Pharmacol. 2026 Apr 1;87(4):229-241. doi: 10.1097/FJC.0000000000001794.
Autores:
Xinyan Li 1 2 , Zhongsu Wang 1 , Juan Liang 1 , Bingsong Li 1 , Qingxin Meng 1 2 , Mei Gao 1
Clin Chem Lab Med. 2026 Jan 6;64(5):1161-1168. doi: 10.1515/cclm-2025-1605. Print 2026 Apr 24.
Autores:
Caroline A E Bachmeier 1 2 3 , Greg J Ward 2 , Andrew J Kassianos 1 4 5 , Alex Dechavez 2 , Chantelle Ebersohn 2 , Andrew Liu 6 , Karam M Kostner 1 7
Conclusión: Point of care testing could be a complimentary option to laboratory testing of lipoprotein(a), especially in remote areas. It may help (re-)stratify cardiovascular risk and help tailor treatment decisions.
Eur J Cardiovasc Nurs. 2026 Apr 3;25(1):119-128. doi: 10.1093/eurjcn/zvaf174.
Autores:
Catriona Sian Jennings 1 , Eanna Kenny 1 , Dirk De Bacquer 2 , Jaimini Cegla 3 , Kausik Kumar Ray 3 , John-Paul Corry 4 , Agnieszka Adamska 1 , Kornelia Kotseva 1 3 , John W McEvoy 1 , Chris Noone 1 , Sandra Ganly 1 , Juwairia Alali 5 , Wael Al Mahmeed 6 , Nooshin Bazargani 7 , Junbo Ge 8 , Rose Hui-Chin Jong 9 , Diana Hui-Ping Foo 9 , Yong Huo 10 , Paula Luna Bonilla 11 , Nancy Xinrong Ji 12 , Piotr Jankowski 13 , Yong Li 14 , Amam Mbakwem 15 , Lilian Kagure Mbau 16 , Okechukwu Samuel Ogah 17 , Elijah N Ogola 18 , Adalberto Elias Quintero-Baiz 19 , Mahmoud Umar Sani 20 , Miguel A Urina-Triana 19 , Renata Wolfshaut-Wolak 21 , Ahmad Syadi Mahmood Zuhdi 22 , David Allan Wood 1 3
Conclusión: Health professionals working in CVD care should be aware of the need to investigate patients with coronary disease for Lp(a) and be equipped to give advice on how to reduce overall cardiovascular risk especially given the absence of licenced therapies to treat Lp(a).
JAMA Netw Open. 2026 Apr 1;9(4):e265199. doi: 10.1001/jamanetworkopen.2026.5199.
Autores:
Rui Tang 1 , Jaejin An 2 3 , Brandon K Bellows 1 , Andrew E Moran 1 , Norrina B Allen 4 , John T Wilkins 4 , Vanessa Xanthakis 5 , Michael Y Tsai 6 , Nilay S Shah 4 , Kristi Reynolds 2 3 , Yiyi Zhang 1
Conclusión y Relevancia: In this cohort study of 10 519 adults, adding apoB to PREVENT-estimated ASCVD risks was associated with improved risk reclassification, particularly in younger adults. However, the clinical importance of these modest improvements remains uncertain.
Clin Cardiol. 2026 Apr;49(4):e70289. doi: 10.1002/clc.70289.
Autores:
Yongmei He 1 , Jun Liu 1 , Jingwei Zhuang 1 , Hongjia Hu 1
Conclusión: Elevated Lp(a) is associated with an increased HF risk in a nonlinear pattern, with risk escalation slowing at higher concentrations.
Zh Nevrol Psikhiatr Im S S Korsakova. 2026;126(3. Vyp. 2):5-11. doi: 10.17116/jnevro20261260325.
[Article in Russian]
Autores:
N V Pizova 1 , A V Pizov 2
J Am Heart Assoc. 2026 Apr 7;15(7):e046519. doi: 10.1161/JAHA.125.046519. Epub 2026 Mar 18.
Autores:
Shyon Parsa 1 , Priyansh Shah 2 , Adam Furst 3 4 , Ramzi Dudum 5 , Natasha Din 4 , David Maron 3 , Paul Heidenreich 3 4 , Jonathan H Ward 6 , Anthony Lozama 6 , Alexander T Sandhu 3 4 , Fatima Rodriguez 1 3 7
Conclusión: Lp(a) testing was associated with increased LLTI and LDL-C goal attainment. Elevated Lp(a) identified individuals more likely to undergo LLTI, suggesting testing may motivate preventive treatment optimization.
Diabetes Obes Metab. 2026 May;28(5):4137-4147. doi: 10.1111/dom.70603. Epub 2026 Feb 27.
Autores:
Xiaozhao Lu 1 2 , Ziyao Yuan 1 2 , Xiaoyu Lin 3 , Zuxian Huang 1 2 , Ziwei Zhou 4 5 , Haozhang Huang 1 2 , Yingying Li 6 , Shaozhao Zhang 4 5 , Ziwen Hui 4 5 , Yihang Ling 1 2 , Wei Guo 1 2 7 , Shiqun Chen 1 2 8 , Jiyan Chen 1 2 , Jin Liu 1 2 , Xiaodong Zhuang 4 5 , Yong Liu 1 2
Conclusión: In patients with CAD, elevated Lp(a) and DM act synergistically to increase the risk of cardiovascular and all-cause mortality, suggesting that both risks should be considered to integrate management.
Diabetes Obes Metab. 2026 May;28(5):3632-3643. doi: 10.1111/dom.70540. Epub 2026 Feb 9.
Autores:
Jun-Xu Gu 1 , Juan Huang 2 , Ai-Min Zhang 1 , Zi-Wei Wang 1 , Hui-Zhang Bao 1 , Yue Yin 1 , Shan-Shan Li 1 , Na Zhang 1 , Li Qin 1 , Zhi-Hong Yue 1 , Kun Wang 3 , Mei Jia 1 , Chun-Yan Wang 1 , Lin Pei 1 , Ming Su 1
Conclusión: Ox-HDL-C, ox-LDL-C and ox-Lp(a) are independent, dose-dependent predictors of T2DM development in individuals with prediabetes. Their close association with impaired β-cell function highlights their potential utility in early risk stratification and targeted prevention strategies for T2DM.
Can J Cardiol. 2026 Apr;42(4):867-884. doi: 10.1016/j.cjca.2025.12.060. Epub 2026 Jan 14.
Autores:
George Thanassoulis 1 , Sonia Anand 2 , Benoit J Arsenault 3 , Kevin R Bainey 4 , Alan D Bell 5 , Liam R Brunham 6 , Iulia Iatan 7 , Marlys L Koschinsky 8 , Lawrence A Leiter 9 , Shamir R Mehta 10 , A Shekhar Pandey 11 , Glen J Pearson 12 ; Canadian Lp(a) Working Group
Zh Nevrol Psikhiatr Im S S Korsakova. 2026;126(3. Vyp. 2):5-11. doi: 10.17116/jnevro20261260325.
[Article in Russian]
Autores:
N V Pizova 1 , A V Pizov 2
Clin Cardiol. 2026 Apr;49(4):e70289. doi: 10.1002/clc.70289.
Autores:
Yongmei He 1 , Jun Liu 1 , Jingwei Zhuang 1 , Hongjia Hu 1
Conclusión: Elevated Lp(a) is associated with an increased HF risk in a nonlinear pattern, with risk escalation slowing at higher concentrations.
JAMA Netw Open. 2026 Apr 1;9(4):e265199. doi: 10.1001/jamanetworkopen.2026.5199.
Autores:
Rui Tang 1 , Jaejin An 2 3 , Brandon K Bellows 1 , Andrew E Moran 1 , Norrina B Allen 4 , John T Wilkins 4 , Vanessa Xanthakis 5 , Michael Y Tsai 6 , Nilay S Shah 4 , Kristi Reynolds 2 3 , Yiyi Zhang 1
Conclusión y relevancia: In this cohort study of 10 519 adults, adding apoB to PREVENT-estimated ASCVD risks was associated with improved risk reclassification, particularly in younger adults. However, the clinical importance of these modest improvements remains uncertain.
J Clin Lipidol. 2026 Apr;20(4):778-788. doi: 10.1016/j.jacl.2026.02.002.
Autores:
Watsapon Chuanchai 1 , Patavee Pajareya 1 , Noppachai Siranart 1 , Somkiat Phutinart 1 , Walit Sowalertrat 2 , Paweenuch Laojindapun 3 , Witina Techasatian 4
Conclusión: High Lp(a) level in patients who underwent PCI with DES was associated with poor prognosis; however, the predictive value of Lp(a) in this population remains inconclusive.
J Clin Lipidol. 2026 Apr;20(4):778-788. doi: 10.1016/j.jacl.2026.02.002.
Autores:
Watsapon Chuanchai 1 , Patavee Pajareya 1 , Noppachai Siranart 1 , Somkiat Phutinart 1 , Walit Sowalertrat 2 , Paweenuch Laojindapun 3 , Witina Techasatian 4
Conclusión: High Lp(a) level in patients who underwent PCI with DES was associated with poor prognosis; however, the predictive value of Lp(a) in this population remains inconclusive.
J Am Heart Assoc. 2026 Apr 21;15(8):e045533. doi: 10.1161/JAHA.125.045533. Epub 2026 Apr 9.
Autores:
Rebecca K Kelly 1 2 , Katie Harris 1 , Paul Muntner 3 4 , Mark Woodward 1 5
Conclusión: Men had a higher rate of CVD than women overall. Low-density lipoprotein cholesterol, apoB and Lp(a) had stronger associations with CVD risk in men, whereas triglycerides were stronger in women. ApoA1 was less protective for CVD in women than men.
Atherosclerosis. 2026 Apr:415:120723. doi: 10.1016/j.atherosclerosis.2026.120723. Epub 2026 Mar 24.
Autores:
Iyas Daghlas 1 , Marios K Georgakis 2 , Stephen O Brennan 3 , Benoit J Arsenault 4 , Stephen Burgess 5 , Dipender Gill 6
Conclusión: These findings suggest that Lp(a) minimally mediates and does not modify the cardiovascular benefits of IL-6 signaling inhibition, supporting these targets as independent and complementary for ASCVD. The amplified IL-6-Lp(a) association in carriers of Lp(a)-raising variants warrants replication.
Atherosclerosis. 2026 Apr:415:120706. doi: 10.1016/j.atherosclerosis.2026.120706. Epub 2026 Mar 13.
Autores:
Sneha Annie Sebastian 1 , Tia Bimal 2 , Tanesh Ayyalu 3 , Natasha Vartak 4 , Harpreet S Bhatia 5 , Sotirios Tsimikas 5
Conclusión: High-risk Lp(a) is associated with greater coronary plaque prevalence, accelerated progression, and increased LAP. These findings underscore Lp(a) as a driver of high-risk, rupture-prone plaques and a critical biomarker and potential therapeutic target in cardiovascular risk management.
Circ J. 2026 Apr 24;90(5):480-489. doi: 10.1253/circj.CJ-25-0847. Epub 2026 Feb 27.
Autores:
Hsin-Yin Hsu 1 2 3 , Hsien-Yu Fan 4 , Ming-Chieh Tsai 5 2 3 , Chih-Jun Lai 2 6 , Lee-Ching Hwang 1 3 , Kuo-Liong Chien 2 7 8
Conclusión: Elevated Lp(a) concentrations were causally associated with ASCVD risk, showing a predominantly graded relationship with possible nonlinearity at very high levels, supporting routine Lp(a) measurement and the development of Lp(a)-lowering therapies.
J Clin Lipidol. 2026 Apr;20(4):789-796. doi: 10.1016/j.jacl.2026.02.001. Epub 2026 Feb 10.
Autores:
Prachi Bajpai 1 , Mukta Mantan 2 , Akanksha Mahajan 3 , Aashima Dabas 4 , Bhawna Mahajan 5
Conclusión: Identification of dyslipidemia using conventional parameters may lead to overdiagnosis in nephrotic syndrome during disease remission; the ApoB/ApoA-1 ratio appears to be a better marker.
J Clin Lipidol. 2026 Apr;20(4):828-832. doi: 10.1016/j.jacl.2026.01.016. Epub 2026 Jan 27.
Autores:
Lakshmi Lakkineni 1 , Matthew Waite 2 , Alessia David 3 , Ben Jones 4 , Jaimini Cegla 5
Conclusión: Hence, repeat Lp(a) testing is generally unnecessary but could be considered in those near risk thresholds or those being evaluated for Lp(a)-lowering therapies.